GlassScriptPhysician profile
Benjamin H Hill
NPI 1982644886
$6,907.54
in general payments reported to CMS, 2019-2025
35 companies · $997 in 2025
The $997 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $876 · 2020: $947 · 2021: $1,080 · 2022: $1,026 · 2023: $765 · 2024: $1,216 · 2025: $997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,978.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,094.60 | 2019-2025 | |
| Novo Nordisk INC | $1,089.72 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $838.13 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $659.57 | 2019-2025 | Zepbound, Mounjaro, Kisunla |
| Astrazeneca Pharmaceuticals LP | $626.06 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Sanofi-Aventis U.S. LLC | $306.21 | 2019-2024 | |
| Abbvie INC. | $260.59 | 2021-2025 | |
| Abbott Laboratories | $243.27 | 2021-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $185.09 | 2019-2024 | Xarelto |
| Exact Sciences Corporation | $172.30 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $159.29 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.67 | 2024-2025 | Jardiance, Jascayd, Ofev |
| Esperion Therapeutics, INC. | $141.78 | 2020-2022 | |
| Astellas Pharma US INC | $117.37 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $103.64 | 2020-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $97.85 | 2023-2024 | Vyepti |
| Glaxosmithkline, LLC. | $90.68 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Insulet Corporation | $83.16 | 2021-2025 | Omnipod |
| Allergan, INC. | $59.11 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $57.93 | 2019-2021 | |
| Dexcom, INC. | $57.88 | 2021-2023 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $52.17 | 2024-2025 | Inspire |
| Shield Therapeutics INC | $34.02 | 2023 | Accrufer |
| Idorsia Pharmaceuticals US INC | $29.77 | 2023-2024 | Quviviq |
| Axsome Therapeutics, INC. | $24.22 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $22.96 | 2024-2025 | Voquezna |
| Optinose US, INC. | $22.60 | 2021 | |
| Ossur Americas, INC. | $21.15 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.20 | 2023 | |
| Alexion Pharmaceuticals, INC. | $19.71 | 2022 | |
| Mylan Specialty L.P. | $16.60 | 2020 | |
| Endo Pharmaceuticals INC. | $16.33 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.26 | 2019 | |
| Eisai INC. | $14.53 | 2021 | |
| Nabriva Therapeutics, Plc | $11.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.